Análise da expressão e atividade das ectoenzimas cd39 e cd73 em pacientes com meningioma

Abstract

Meningiomas are the most prevalent primary tumors of the Central Nervous System, grouped into Grade I, Grade II, and Grade III according to criteria established by the World Health Organization. Among the mechanisms involved in tumor modulation, the Purinergic System stands out, participating in the regulation of inflammation, tumor progression, and immunosuppression in various tumor types. Although the components of the Purinergic System are widely studied in other CNS tumors, the literature on its participation in meningiomas is still scarce, aiming at the realization of this study. This is a quantitative, cross-sectional, and comparative study carried out with patients who underwent surgical resection of meningiomas in two reference hospitals in Chapecó-SC between 09/06/2023 and 09/12/2024. The cases in the period reached n=40, however, n=6 had loss of histopathological follow-up in medical records. Therefore, n=40 was only used in the characterization of the sample for analyses that did not require division by grade. In general, the sample was divided according to the following analysis: characterization of the sample Grade I n=28 and Grade II n=34; tumor analysis Grade I n=12 and Grade II n=6; lymphocyte analysis Grade I n=16, Grade II n=4 and Control n=14; serum analysis Grade I n=11, Grade II n=5 and Control n=9. For molecular analysis in the tumor environment (TME), the expression of the CD39 and CD73 genes was evaluated by RT- qPCR. Fisher's exact test was used for statistical analysis of sample characterization aspects. The enzymatic activity of CD39 and CD73 was measured in lymphocytes and ADA activity in serum by kinetic method. The results were calculated according to the technique and were subjected to Mann-Whitney statistical tests for tumor analysis and Kruskal-Wallis for systemic analysis, considering p < 0.05. The results demonstrated a predominance of women (12.3:1), a mean age of 52.9, with a standard deviation of 14.7 years. A higher incidence of Grade II tumors was observed in patients over 65 years of age (p= 0.0180). In tumor tissue, an increase in CD73 expression was observed in Grade I meningiomas compared to Grade II (p= 0.0297), while CD39 did not show significant differences. In lymphocytes, CD39 activity in ATP hydrolysis was significant between Grade II and control (p=0.0386) and between grades (p= 0.0212). CD73 activity was increased in Grade II compared to Grade I (p=0.0299). These findings may suggest an immunological and tumor microenvironment that favors tumor progression. It is concluded that SP markers present relevant alterations in meningiomas that have never been previously described in the literature and divergent findings in the case of CD73 in situ.